SE402709B - Forfarande for framstellning av ett farmaceutiskt preparat for behandling av hyperkolesterolemi, innehallande p-klorfenoxiisosmorsyra eller vissa estrar eller salter derav - Google Patents

Forfarande for framstellning av ett farmaceutiskt preparat for behandling av hyperkolesterolemi, innehallande p-klorfenoxiisosmorsyra eller vissa estrar eller salter derav

Info

Publication number
SE402709B
SE402709B SE7113008A SE1300871A SE402709B SE 402709 B SE402709 B SE 402709B SE 7113008 A SE7113008 A SE 7113008A SE 1300871 A SE1300871 A SE 1300871A SE 402709 B SE402709 B SE 402709B
Authority
SE
Sweden
Prior art keywords
preparation
hypercolesterolemia
estrars
chlorophenoxiisosmoroic
salts
Prior art date
Application number
SE7113008A
Other languages
English (en)
Swedish (sv)
Inventor
A N Howard
Original Assignee
Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Ab filed Critical Pharmacia Ab
Publication of SE402709B publication Critical patent/SE402709B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE7113008A 1970-10-15 1971-10-14 Forfarande for framstellning av ett farmaceutiskt preparat for behandling av hyperkolesterolemi, innehallande p-klorfenoxiisosmorsyra eller vissa estrar eller salter derav SE402709B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB4914070 1970-10-15

Publications (1)

Publication Number Publication Date
SE402709B true SE402709B (sv) 1978-07-17

Family

ID=10451313

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7113008A SE402709B (sv) 1970-10-15 1971-10-14 Forfarande for framstellning av ett farmaceutiskt preparat for behandling av hyperkolesterolemi, innehallande p-klorfenoxiisosmorsyra eller vissa estrar eller salter derav

Country Status (7)

Country Link
US (1) US3846541A (OSRAM)
AU (1) AU458705B2 (OSRAM)
CA (1) CA968272A (OSRAM)
DE (1) DE2151510A1 (OSRAM)
FR (1) FR2110458B1 (OSRAM)
GB (1) GB1348642A (OSRAM)
SE (1) SE402709B (OSRAM)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069306A (en) * 1974-03-14 1978-01-17 Pharmacia Aktiebolag X-ray contrast preparation containing a hydrophilic polymer containing amino groups
FR2382892A1 (fr) * 1977-03-08 1978-10-06 Sarget Lab Nouveau medicament hypolipidemiant a base d'ester de p-chlorophenol de l'acide p-chlorophenoxyisobutyrique
IT1106718B (it) 1978-12-21 1985-11-18 Alfa Farmaceutici Spa Composizioni a base di resine anioniche salificate farmacologicamente attive
US4393145A (en) * 1979-05-01 1983-07-12 Etablissement Texcontor Anionic ion exchange resins with cholesterol-decreasing properties
US4788055A (en) * 1985-12-09 1988-11-29 Ciba-Geigy Corporation Resinate sustained release dextromethorphan composition
EP0276807A3 (en) * 1987-01-27 1988-10-12 Warner-Lambert Company Lipid regulating compositions
US5167965A (en) * 1987-02-09 1992-12-01 The Dow Chemical Company Palatable cholestyramine granules, tablets and methods for preparation thereof
IL85632A (en) * 1987-03-10 1991-08-16 Ciba Geigy Ag Hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resin
US4837255A (en) * 1987-03-10 1989-06-06 Ciba-Geigy Corporation Palatable hypocholesterolaemic gel formulation containing a pharmaceutically acceptable non-digestible anion exchange resin
US4859703A (en) * 1987-06-15 1989-08-22 Warner-Lambert Company Lipid regulating compositions
US5520932A (en) * 1988-06-24 1996-05-28 The Upjohn Company Fine-milled colestipol hydrochloride
IL95574A (en) * 1989-09-09 1994-11-11 Knoll Ag Colestyramine preparation
US20050090553A1 (en) * 1992-06-30 2005-04-28 Shapiro Howard K. Compositions and method for treatment of chronic inflammatory diseases
US8178516B2 (en) * 1992-06-30 2012-05-15 Sylvan Labs, LLC Compositions and method for treatment of chronic inflammatory diseases
US5451397A (en) * 1992-12-21 1995-09-19 Rohm And Haas Company Bile acid sequestrant
US5498678A (en) * 1992-12-21 1996-03-12 Rohm And Haas Company Suspension polymerization process for water-soluble monomers
US7071174B1 (en) * 1994-10-13 2006-07-04 Cv Therapeutics, Inc. Method and composition for inhibiting cholesterol esterase
JP5889321B2 (ja) 2010-11-04 2016-03-22 アルビレオ アクチエボラグ 肝疾患の処置用のｉｂａｔ阻害剤
WO2012064267A1 (en) 2010-11-08 2012-05-18 Albireo Ab A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
CA2842802C (en) * 2011-08-01 2020-03-10 Hb Biotechnologies Corporation Non-digestible capsules for the delivery of fluid absorbing materials
WO2013063512A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
MX363161B (es) 2011-10-28 2019-03-13 Lumena Pharmaceuticals Inc Inhibidores de la recirculación de ácidos biliares para el tratamiento de hipercolemia y enfermedad hepática colestásica.
EP2968230A2 (en) 2013-03-15 2016-01-20 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of primary sclerosing cholangitis and inflammatory bowel disease
MX2015013196A (es) 2013-03-15 2016-04-15 Lumena Pharmaceuticals Inc Inhibidores de reciclaje de acidos biliares para el tratamiento de la enfermedad de reflujo gastroesofagico y esofago de barrett.
PT3923943T (pt) 2019-02-12 2024-10-23 Mirum Pharmaceuticals Inc Resposta dependente da dose e do genótipo a um asbti em doentes com deficiência na bomba de exportação de sais biliares

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB860303A (en) * 1958-06-20 1961-02-01 Ici Ltd Pharmaceutical compositions comprising ª‡-aryloxy-aliphatic carboxylic acids and/or ª
US3042667A (en) * 1959-03-10 1962-07-03 Pharmacia Ab Process for producing dextran derivatives and products resulting therefrom
NL252506A (OSRAM) * 1959-06-12
US3383281A (en) * 1961-09-22 1968-05-14 Merck & Co Inc Method for binding bile acids in vivo
US3308020A (en) * 1961-09-22 1967-03-07 Merck & Co Inc Compositions and method for binding bile acids in vivo including hypocholesteremics
US3627872A (en) * 1968-04-08 1971-12-14 Upjohn Co Oral treatment of hyper-cholesteremia in mammals and birds with ether-type anion exchangers of polysaccharides

Also Published As

Publication number Publication date
DE2151510A1 (de) 1972-04-20
US3846541A (en) 1974-11-05
FR2110458B1 (OSRAM) 1975-02-07
GB1348642A (en) 1974-03-20
AU458705B2 (en) 1975-03-06
FR2110458A1 (OSRAM) 1972-06-02
CA968272A (en) 1975-05-27
AU3451371A (en) 1973-04-19

Similar Documents

Publication Publication Date Title
SE402709B (sv) Forfarande for framstellning av ett farmaceutiskt preparat for behandling av hyperkolesterolemi, innehallande p-klorfenoxiisosmorsyra eller vissa estrar eller salter derav
SE385585B (sv) Forfarande for framstellning av 1-alkyl-1,4-dihydro-4-oxo-3-kinolinkarboxylsyraderivat
NO145883C (no) Analogifremgangsmaate ved fremstilling av terapeutisk aktive 7-methoxy-7-acylamino-cefalosporansyrederivater
DK124547B (da) Analogifremgangsmåde til fremstilling af (3-amino-2-hydroxy-propyloxy)-thiochromanderivater eller syreadditionssalte deraf.
SE425392B (sv) Forfarande for framstellning av nya 5,9-beta-disubstituerade 2-tetrahydrofurfuryl-6,7-bensomorfaner eller deras syraadditionssalter
SE400296B (sv) Forfarande for framstellning av derivat av cyklisk adenosin-3',5'-monofosforsyra
SE398229B (sv) Forfarande for framstellning av 4-fenoxi-fenoxialkankarbonsyraderivat
SE405121B (sv) Forfarande for framstellning av 2-(heteroaryl-metyl)-5-9beta-dialkyl-6,7-bensomorfaner eller deras syraadditionssalter
SE385118B (sv) Forfarande for framstellning av 2-(6-metoxi-2-naftyl)-propionsyra
NO143575C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive prostansyre-derivater
SE409460B (sv) Forfarande for framstellnoing av farmaceutiskt godtagbara syraadditionssalter av aminoglykosidantibiotika
SE396011B (sv) Forfarande for framstellning av en i huvudsak klar, steril vattenlosning av 1,3-bis(2-karboxikromon-5-yloxi)-propan-2-ol eller ett farmaceutiskt godtagbart salt derav
NO146241C (no) Fremgangsmaate til fremstilling av hetacephalexin eller salter derav
NO153299C (no) Fremgangsmaate for fremstilling av 6-d-alfa-amino-alfa-(p-hydroksy-fenyl)-acetamido-penicillansyre eller salter derav.
SE400551B (sv) Forfarande for framstellning av terapeutiskt aktiva 3-amino-5-karbamylbensoesyraderivat
SE416729B (sv) Forfarande for framstellning av salter av p-dihydroxibensendisulfonsyra
DK131778B (da) Fremgangsmåde til fremstilling af substituerede 3-hydroksymetylisokinolinderivater eller syreadditionssalte heraf.
SE402009B (sv) Forfarande for framstellning av 9-desoxi-prosta-5,9,(10),13-triensyraderivat
SE393801B (sv) Forfarande for framstellning av tiokarbaminsyraderivat med antifungistatisk lekemedelsverken
DK131857B (da) Analogifremgangsmåde til fremstilling af 4-hydroxymethyl-1-phthalazonderivater eller syreadditionssalte deraf.
DK138943B (da) Analogifremgangsmåde til fremstilling af substituerede dibenzocyclohepten-carboxamider eller syreadditionssalte deraf.
DK130958B (da) Analogifremgangsmåde til fremstilling af racemiske eller optisk aktive 1-phenoxy-2-hydroxy-3-hydroxyalkylaminopropaner eller fysiologisk tålelige syreadditionssalte heraf.
DK137044B (da) Analogifremgangsmåde til fremstilling af 4,4-diphenylhexahydroazepinderivater eller syreadditionssalte deraf.
SE431216B (sv) Forfarande for framstellning av 1n-(alfa-hydroxi-omega-amino-alkanoyl)-6 721n-metyl-3 721, 4 721-dideoxikanamycin b eller farmaceutiskt godtagbara syraadditionssalter derav
DK138540B (da) Analogifremgangsmåde til fremstilling af benzhydryloxyalkylaminderivater eller farmaceutisk acceptable syreadditionssalte deraf.